Cover Image
市場調查報告書

囊狀纖維化症的歐洲市場

Cystic Fibrosis Market in Europe 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 324716
出版日期 內容資訊 英文 113 Pages
訂單完成後即時交付
價格
Back to Top
囊狀纖維化症的歐洲市場 Cystic Fibrosis Market in Europe 2015-2019
出版日期: 2015年02月18日 內容資訊: 英文 113 Pages
簡介

囊狀纖維化症,是遺傳性疾病之1,最常見於白色人種的兒童。歐洲的囊狀纖維化症市場,2014年∼2019年預計以35.1%的年複合成長率成長。

本報告提供歐洲的囊狀纖維化症市場相關調查分析、市場規模與成長率、市場趨勢、市場的推動要素與課題、市場機會驗證、主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 產品簡介

  • Zenpep
  • Colomycin/Colobreathe
  • Pulmozyme
  • Cayston
  • TOBI/TOBI Podhaler
  • Kalydeco

第6章 簡介

第7章 疾病概要

  • 理解病
  • 病理學
  • 流行病學
    • 全球
    • 英國
  • 診斷
    • 帶菌者檢驗
    • 生產前檢驗
    • 新生兒診察
    • 其他檢驗
  • 囊狀纖維化症的徵兆
  • 經濟負擔

第8章 開發平台的組合

第9章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第10章 歐洲的囊狀纖維化症市場區分:各分子類型

  • 生技藥品
    • 酵素
  • 小分子
    • CFTR調製器
    • 抗生素

第11章 歐洲的囊狀纖維化症市場區分:各給藥途徑

  • 口服
  • 非口服
  • 局部

第12章 歐洲的囊狀纖維化症市場區分:各投藥形態

  • 固體
  • 液體

第13章 主要國家

  • 英國
  • 法國
  • 義大利
  • 德國
  • 西班牙

第14章 購買標準

第15章 推動市場成長要素

第16章 成長推動因素與其影響

第17章 市場課題

第18章 成長推動因素與課題的影響

第19章 市場趨勢

第20章 趨勢與其影響

第21章 業者情勢

  • 競爭模式
  • 市場佔有率分析
  • 其他/未來的有力供應商

第22章 主要供應商分析

  • Actavis
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • Novartis
  • Vertex Pharmaceuticals

第23章 相關報告

圖表

目錄
Product Code: IRTNTR5271

About Cystic Fibrosis

Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited disease. The primary symptoms of cystic fibrosis include high salt content in the sweat, breathing difficulties, secretion of abnormally viscous mucus, respiratory complications, difficulties related to digestion, and growth anomalies. Cystic fibrosis is one of the most common genetic disorders observed in Caucasian children. Rare diseases are those that affect less than 5 patients per 10,000, as defined in the EU by Rare Disease UK. Cystic fibrosis is therefore classified under rare diseases. The incidence of cystic fibrosis varies between populations. It is significantly less common in Asian and African populations compared to Caucasians (people from Europe, North America, and Australasia), with a marked difference between each country in those regions. Precise data regarding the prevalence of cystic fibrosis in Europe is not available, but it is estimated to be 1 in 8,000-10,000 individuals. Cystic fibrosis is a chronic disease and is usually progressive in nature. The onset of cystic fibrosis typically occurs in early childhood or, rarely, at birth. The principal manifestations of cystic fibrosis in patients are chronic bronchitis, pancreatic insufficiency, adolescent diabetes, pancreatitis, male sterility, and very rarely intestinal obstruction or liver cirrhosis. The mortality and morbidity of patients are dependent on the degree of bronchopulmonary involvement.

TechNavio's analysts forecast the Cystic Fibrosis market in Europe to grow at a CAGR of 35.10 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Cystic Fibrosis market in Europe for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of cystic fibrosis including:

  • Small Molecules
  • Biologics

TechNavio's report, Cystic Fibrosis Market in Europe 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers data from Europe; it also covers the market landscape of the Cystic Fibrosis market in Europe and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors

  • Actavis
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • Novartis
  • Vertex Pharmaceuticals

Other Prominent Vendors

  • Abbott
  • Anthera Pharmaceuticals
  • Arcturus Therapeutics
  • Boehringer Ingelheim
  • Chiesi Farmaceutici
  • Corbus Pharmaceuticals
  • Genzyme
  • Insmed
  • Johnson & Johnson
  • Merck Sharp & Dohme
  • Neovii Biotech
  • Novo Nordisk
  • PharmaSwiss
  • Pharmaxis
  • Proteostasis Therapeutics
  • PTC Therapeutics
  • United Medical
  • Venus Remedies

Market Driver

  • Unmet Needs
  • For a full, detailed list, view our report

Market Challenge

  • High Cost of Treatments
  • For a full, detailed list, view our report

Market Trend

  • Rise in Public Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Product Profiles

    • 05.1.1. Zenpep
    • 05.1.2. Colomycin/Colobreathe
    • 05.1.3. Pulmozyme
    • 05.1.4. Cayston
    • 05.1.5. TOBI/TOBI Podhaler
    • 05.1.6. Kalydeco

06. Introduction

07. Disease Overview

  • 07.1. Understanding the Disease
  • 07.2. Pathophysiology
  • 07.3. Epidemiology
    • 07.3.1. Global
    • 07.3.2. UK
  • 07.4. Diagnosis
    • 07.4.1. Carrier Testing
    • 07.4.2. Antenatal Testing
    • 07.4.3. Newborn Screening
    • 07.4.4. Other Tests
  • 07.5. Manifestations of Cystic Fibrosis
  • 07.6. Economic Burden

08. Pipeline Portfolio

09. Market Landscape

  • 09.1. Market Overview
  • 09.2. Market Size and Forecast
  • 09.3. Five Forces Analysis

10. Segmentation of Cystic Fibrosis Market in Europe by Molecule Type

  • 10.1. Biologics
    • 10.1.1. Enzymes
  • 10.2. Small Molecules
    • 10.2.1. CFTR Modulators
    • 10.2.2. Antibiotics

11. Segmentation of Cystic Fibrosis Market in Europe by Route of Administration

  • 11.1. Oral
  • 11.2. Parenteral
  • 11.3. Topical

12. Segmentation of Cystic Fibrosis Market in Europe by Dosage Form

  • 12.1. Solid
  • 12.2. Liquid

13. Key Leading Countries

  • 13.1. UK
  • 13.2. France
  • 13.3. Italy
  • 13.4. Germany
  • 13.5. Spain

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

  • 21.1. Competitive Scenario
    • 21.1.1. Key News
    • 21.1.2. Mergers and Acquisitions
  • 21.2. Market Share Analysis 2014
    • 21.2.1. Actavis
    • 21.2.2. F. Hoffmann-La Roche
    • 21.2.3. Gilead Sciences
    • 21.2.4. Novartis
    • 21.2.5. Vertex Pharmaceuticals
  • 21.3. Other and Future Prominent Vendors

22. Key Vendor Analysis

  • 22.1. Actavis
    • 22.1.1. Key Facts
    • 22.1.2. Business Description
    • 22.1.3. Business Segmentation
    • 22.1.4. Business Segmentation by Revenue 2012 and 2013
    • 22.1.5. Sales by Geography
    • 22.1.6. Business Strategy
    • 22.1.7. Key Information
    • 22.1.8. SWOT Analysis
  • 22.2. F. Hoffmann-La Roche
    • 22.2.1. Key Facts
    • 22.2.2. Business Overview
    • 22.2.3. Business Segmentation
    • 22.2.4. Business Segmentation by Revenue 2012 and 2013
    • 22.2.5. Sales by Geography
    • 22.2.6. Business Strategy
    • 22.2.7. Key Information
    • 22.2.8. SWOT Analysis
  • 22.3. Gilead Sciences
    • 22.3.1. Key Facts
    • 22.3.2. Business Overview
    • 22.3.3. Geographical Segmentation by Revenue 2013
    • 22.3.4. Recent Developments
    • 22.3.5. SWOT Analysis
  • 22.4. Novartis
    • 22.4.1. Key Facts
    • 22.4.2. Business Description
    • 22.4.3. Business Segmentation
    • 22.4.4. Revenue by Business Segmentation
    • 22.4.5. Revenue Comparison 2012 and 2013
    • 22.4.6. Sales by Geography
    • 22.4.7. Business Strategy
    • 22.4.8. Key Developments
    • 22.4.9. SWOT Analysis
  • 22.5. Vertex Pharmaceuticals
    • 22.5.1. Key Facts
    • 22.5.2. Business Overview
    • 22.5.3. Business Segmentation by Revenue 2013
    • 22.5.4. Business Segmentation by Revenue 2012 and 2013
    • 22.5.5. Geographical Segmentation by Revenue 2013
    • 22.5.6. Business Strategy
    • 22.5.7. Recent Developments
    • 22.5.8. SWOT Analysis

23. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Snapshot of Cystic Fibrosis
  • Exhibit 3: Defects Caused by CFTR Mutation
  • Exhibit 4: Prevalence Rate of Cystic Fibrosis by Country 2014
  • Exhibit 5: Prevalence of Cystic Fibrosis by Country 2014 (million)
  • Exhibit 6: Forecast for Prevalence of Cystic Fibrosis in UK 2014-2019 (million)
  • Exhibit 7: Age Distribution of Cystic Fibrosis Patients in UK at Death 2013 (in years)
  • Exhibit 8: Age Distribution of Cystic Fibrosis Patients in UK by Gender 2013
  • Exhibit 9: Age Distribution of Cystic Fibrosis Patients in UK by Sex 2013
  • Exhibit 10: Diagnosis of Cystic Fibrosis
  • Exhibit 11: Manifestations of Cystic Fibrosis
  • Exhibit 12: Snapshot of Economic Burden of Cystic Fibrosis
  • Exhibit 13: Pipeline Snapshot of Cystic Fibrosis Drugs
  • Exhibit 14: Cystic Fibrosis Market in Europe 2014-2019 (US$ million)
  • Exhibit 15: Segmentation of Cystic Fibrosis Market in Europe by Molecule Type
  • Exhibit 16: Cystic Fibrosis Market in Europe by Molecule Type 2014
  • Exhibit 17: Segmentation of Cystic Fibrosis Market in Europe by Route of Administration
  • Exhibit 18: Cystic Fibrosis Market in Europe by Route of Administration 2014
  • Exhibit 19: Segmentation of Cystic Fibrosis Market in Europe by Dosage Form
  • Exhibit 20: Cystic Fibrosis Market in Europe by Dosage Form 2014
  • Exhibit 21: Buying Criteria in Cystic Fibrosis Market in Europe
  • Exhibit 22: Drivers and their Impact on the Key Customer Category of the Cystic Fibrosis Market in Europe
  • Exhibit 23: Cystic Fibrosis Market in Europe Market Share Analysis 2014
  • Exhibit 24: Global Sales of Pulmozyme 2012 and 2013 (US$ million)
  • Exhibit 25: Quarterly Global Sales of Pulmozyme 1994-2008 (US$ million)
  • Exhibit 26: Quarterly Sales of Pulmozyme to Collaborators 1997-2008 (US$ million)
  • Exhibit 27: TOBI Podhaler
  • Exhibit 28: Comparison of YoY Global Sales of TOBI and TOBI Podhaler 2006-2013 (US$ million)
  • Exhibit 29: Comparison of YoY Global Sales of Kalydeco 2012-2013 (US$ million)
  • Exhibit 30: Cystic Fibrosis Market in Europe Business Segmentation 2013
  • Exhibit 31: Cystic Fibrosis Market in Europe Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 32: Actavis : Sales by Geography (in US$ million)
  • Exhibit 33: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
  • Exhibit 34: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 35: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 36: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 37: Gilead Sciences: Geographical Segmentation by Revenue 2013
  • Exhibit 38: Novartis AG: Business Segmentation
  • Exhibit 39: Novartis AG: Revenue by Business Segmentation 2013
  • Exhibit 40: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 41: Novartis AG: Revenue by Geographical Segmentation 2013
  • Exhibit 42: Vertex Pharmaceuticals: Business Segmentation by Revenue 2013
  • Exhibit 43: Vertex Pharmaceuticals: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 44: Vertex Pharmaceuticals: Geographical Segmentation by Revenue 2013
Back to Top